Eflapegrastim
Leukocyte Growth Factor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: eflapegrastim-xnst, HM10460A, HNK460, rolvedon, SPI-2012
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Eflapegrastim is a drug in the Leukocyte Growth Factor class catalogued in DrugCentral. It was first approved by the FDA in 2022. DrugCentral lists 1 molecular target, including CSF3R. Recorded indications include Febrile neutropenia caused by myelosuppressive anti-cancer drugs.
- Drug class: Leukocyte Growth Factor.
- Molecular targets: CSF3R (1 listed in DrugCentral).
- Indications: Febrile neutropenia caused by myelosuppressive anti-cancer drugs.
- ATC code: L03AA19 (Colony stimulating factors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Febrile neutropenia caused by myelosuppressive anti-cancer drugs
Mechanism & targets
| Established pharmacologic class | Leukocyte Growth Factor |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Granulocyte colony-stimulating factor receptor | CSF3R | agonist | Kd 8.44 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2022-09-09 | FDA | — | SPECTRUM PHARMS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L03AA19 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Colony stimulating factors |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 1384099-30-2 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Eflapegrastim used for?
DrugCentral lists the following indications for Eflapegrastim: Febrile neutropenia caused by myelosuppressive anti-cancer drugs.
How does Eflapegrastim work?
Its molecular targets in DrugCentral include CSF3R (agonist).
When was Eflapegrastim first approved?
Eflapegrastim was first approved by the FDA in 2022.
What drug class does Eflapegrastim belong to?
Eflapegrastim is in the Leukocyte Growth Factor class.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5678 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3833384 — compound record and bioactivity
- DrugBank DB15001 — drug record
- FDA UNII UT99UG9QJX — substance identity
- DailyMed: FDA labels for Eflapegrastim — current prescribing information (label search)
- UniProt Q99062 (CSF3R) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.